Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
08 Nov 2021
08 Nov 2021
Historique:
received:
02
03
2021
accepted:
01
10
2021
entrez:
9
11
2021
pubmed:
10
11
2021
medline:
10
11
2021
Statut:
epublish
Résumé
Influenza viruses cause a significant number of infections and deaths annually. In addition to seasonal infections, the risk of an influenza virus pandemic emerging is extremely high owing to the large reservoir of diverse influenza viruses found in animals and the co-circulation of many influenza subtypes which can reassort into novel strains. Development of a universal influenza vaccine has proven extremely challenging. In the absence of such a vaccine, rapid response technologies provide the best potential to counter a novel influenza outbreak. Here, we demonstrate that a modular trimerization domain known as the molecular clamp allows the efficient production and purification of conformationally stabilised prefusion hemagglutinin (HA) from a diverse range of influenza A subtypes. These clamp-stabilised HA proteins provided robust protection from homologous virus challenge in mouse and ferret models and some cross protection against heterologous virus challenge. This work provides a proof-of-concept for clamp-stabilised HA vaccines as a tool for rapid response vaccine development against future influenza A virus pandemics.
Identifiants
pubmed: 34750396
doi: 10.1038/s41541-021-00395-4
pii: 10.1038/s41541-021-00395-4
pmc: PMC8575991
doi:
Types de publication
Journal Article
Langues
eng
Pagination
135Subventions
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP1156063
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP1156063
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP1156063
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP1156063
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
World Health Organisation. Influenza (Seasonal), http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) (2018).
Frost, W. H. Statistics of influenza morbidity: with special reference to certain factors in case incidence and case fatality. Public Health Rep. 35, 584–597 (1920).
doi: 10.2307/4575511
Nabel, G. J., Wei, C.-J. & Ledgerwood, J. E. Vaccinate for the next H2N2 pandemic now. Nature 471, 157–158 (2011).
pubmed: 21390107
doi: 10.1038/471157a
Centres for Disease Control and Prevention. Influenza: 1968 Pandemic (H3N2 Virus), https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html (2016).
Dawood, F. S. et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12, 687–695 (2012).
pubmed: 22738893
doi: 10.1016/S1473-3099(12)70121-4
LaRussa, P. Pandemic novel 2009 H1N1 influenza: what have we learned? Semin. Respir. Crit. Care Med. 32, 393–399 (2011).
pubmed: 21858744
doi: 10.1055/s-0031-1283279
World Health Organisation. Summary of Key Information Practical to Countries Experiencing Outbreaks of A(H5N1) and Other Subtypes of Avian Influenza (First Edition), http://www.who.int/influenza/publications/avian_influenza_packagev1/en/ (2016).
World Health Organisation. H7N9 situation update, http://www.fao.org/ag/againfo/programmes/en/empres/h7n9/situation_update.html (2016).
World Health Organisation. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2016, http://www.who.int/influenza/human_animal_interface/2016_07_19_tableH5N1.pdf?ua=1 (2016).
Manz, B. et al. Multiple natural substitutions in Avian Influenza A virus PB2 facilitate efficient replication in human cells. J. Virol. 90, 5928–5938 (2016).
pubmed: 27076644
pmcid: 4907234
doi: 10.1128/JVI.00130-16
Yamaji, R. et al. Identification of PB2 mutations responsible for the efficient replication of H5N1 influenza viruses in human lung epithelial cells. J. Virol. 89, 3947–3956 (2015).
pubmed: 25609813
pmcid: 4403392
doi: 10.1128/JVI.03328-14
de Bruin, E., Zhang, X., Ke, C., Sikkema, R. & Koopmans, M. Serological evidence for exposure to avian influenza viruses within poultry workers in southern China. Zoonoses Public Health 64, e51–e59 (2017).
doi: 10.1111/zph.12346
pubmed: 28220658
Zhou, L. et al. Clusters of Human Infection and Human-to-Human Transmission of Avian Influenza A(H7N9) Virus, 2013–2017. Emerg. Infect. Dis. 24, https://doi.org/10.3201/eid2402.171565 (2018).
Bergervoet, S. A., Ho, C. K. Y., Heutink, R., Bossers, A. & Beerens, N. Spread of highly pathogenic avian influenza (HPAI) H5N5 viruses in Europe in 2016-2017 appears related to the timing of reassortment events. Viruses 11, 501 (2019).
pmcid: 6631432
doi: 10.3390/v11060501
Gu, M. et al. Novel reassortant highly pathogenic avian influenza (H5N5) viruses in domestic ducks, China. Emerg. Infect. Dis. 17, 1060–1063 (2011).
pubmed: 21749770
pmcid: 3358203
doi: 10.3201/eid/1706.101406
Centre for Disease Control and Prevention. Influenza Vaccine Advances, https://www.cdc.gov/flu/about/qa/advances.htm (2016).
Centres for Disease Control and Prevention. Past Seasons Vaccine Effectiveness Estimates, https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html (2020).
Pandey, A., Singh, N., Sambhara, S. & Mittal, S. K. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum. Vaccin 6, 178–188 (2010).
doi: 10.4161/hv.6.2.9899
pubmed: 19875936
Ellebedy, A. H. et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl Acad. Sci. USA 111, 13133–13138 (2014).
pubmed: 25157133
pmcid: 4246941
doi: 10.1073/pnas.1414070111
Nachbagauer, R. et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88, 13260–13268 (2014).
pubmed: 25210189
pmcid: 4249097
doi: 10.1128/JVI.02133-14
Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Investig. 120, 1663–1673 (2010).
pubmed: 20389023
pmcid: 2860935
doi: 10.1172/JCI41902
Thomson, C. A. et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front. Immunol. 3, 87 (2012).
pubmed: 22586427
pmcid: 3347682
doi: 10.3389/fimmu.2012.00087
Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542–6550 (2013).
pubmed: 23576508
pmcid: 3676110
doi: 10.1128/JVI.00641-13
Krammer, F. et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88, 2340–2343 (2014).
pubmed: 24307585
pmcid: 3911549
doi: 10.1128/JVI.03183-13
Liao, H.-Y. et al. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes. Proc. Natl Acad. Sci. 117, 17757–17763 (2020).
pubmed: 32669430
pmcid: 7395492
doi: 10.1073/pnas.2004783117
Kirkpatrick, E., Qiu, X., Wilson, P. C., Bahl, J. & Krammer, F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8, 10432–10432 (2018).
pubmed: 29992986
pmcid: 6041311
doi: 10.1038/s41598-018-28706-1
Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011).
doi: 10.1126/science.1205669
pubmed: 21798894
Friesen, R. H. et al. A common solution to group 2 influenza virus neutralization. Proc. Natl Acad. Sci. USA 111, 445–450 (2014).
doi: 10.1073/pnas.1319058110
pubmed: 24335589
Tan, G. S. et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of Group 2 Influenza A virus hemagglutinin. J. Virol. 88, 13580–13592 (2014).
pubmed: 25210195
pmcid: 4248980
doi: 10.1128/JVI.02289-14
Wang, W. et al. Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses. Nat. Commun. 7, 13577 (2016) https://www.nature.com/articles/ncomms13577#supplementary-information ..
Gerhard, W., Mozdzanowska, K. & Zharikova, D. Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 12, 569–574 (2006).
pubmed: 16704803
pmcid: 3294695
doi: 10.3201/eid1204.051020
Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699–704 (2014).
pubmed: 24155380
pmcid: 3911724
doi: 10.1128/JVI.02608-13
Krammer, F. et al. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7, e43603 (2012).
pubmed: 22928001
pmcid: 3426533
doi: 10.1371/journal.pone.0043603
Wohlbold, T. J. et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33, 3314–3321 (2015).
pubmed: 26026378
pmcid: 4472732
doi: 10.1016/j.vaccine.2015.05.038
Weldon, W. C. et al. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS ONE 5, e12466 (2010).
pubmed: 20824188
pmcid: 2931692
doi: 10.1371/journal.pone.0012466
Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015).
pubmed: 26303961
doi: 10.1126/science.aac7263
Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. advance online publication, https://doi.org/10.1038/nm.3927 http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm.3927.html#supplementary-information (2015).
Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl Acad. Sci. USA 111, 125–130 (2014).
doi: 10.1073/pnas.1308701110
pubmed: 24344259
Sagawa, H., Ohshima, A., Kato, I., Okuno, Y. & Isegawa, Y. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 77, 1483–1487 (1996).
pubmed: 8757990
doi: 10.1099/0022-1317-77-7-1483
Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1, https://doi.org/10.1128/mBio.00018-10 (2010).
Bommakanti, G. et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J. Virol. 86, 13434–13444 (2012).
pubmed: 23015722
pmcid: 3503045
doi: 10.1128/JVI.01429-12
Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl Acad. Sci. USA 111, E2514–2523 (2014).
pubmed: 24927560
pmcid: 4078824
doi: 10.1073/pnas.1402766111
Mallajosyula, V. V. A. et al. Hemagglutinin sequence conservation guided stem immunogen design from Influenza A H3 subtype. Front. Immunol. 6, 329 (2015).
pubmed: 26167164
pmcid: 4481277
doi: 10.3389/fimmu.2015.00329
Valkenburg, S. A. et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci. Rep. 6, 22666 (2016) http://www.nature.com/articles/srep22666#supplementary-information ..
Wang, S.-C., Liao, H.-Y., Zhang, J.-Y., Cheng, T.-J. R. & Wong, C.-H. Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris. Virology 526, 125–137 (2019).
doi: 10.1016/j.virol.2018.10.005
pubmed: 30388628
Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478 (2020).
pubmed: 32702298
pmcid: 7445431
doi: 10.1016/S0140-6736(20)31604-4
Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020).
pubmed: 32663912
doi: 10.1056/NEJMoa2022483
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
pubmed: 32433465
pmcid: 7239918
doi: 10.1038/s41467-020-16505-0
Wijesundara, D. K. et al. Rapid response subunit vaccine design in the absence of structural information. Front. Immunol. 11, https://doi.org/10.3389/fimmu.2020.592370 (2020).
Watterson, D. A. W. et al. Rapid application of the molecular clamp platform for SARS-CoV-2. SSRN, https://doi.org/10.2139/ssrn.3736395 (2020).
Meier, S., Güthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable β-hairpin: atomic details of trimer dissociation and local β-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051–1069 (2004).
doi: 10.1016/j.jmb.2004.09.079
pubmed: 15544812
Wiley, D. C., Skehel, J. J. & Waterfield, M. Evidence from studies with a cross-linking reagent that the haemagglutinin of influenza virus is a trimer. Virology 79, 446–448 (1977).
doi: 10.1016/0042-6822(77)90371-3
pubmed: 867833
Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 289, 366–373 (1981).
doi: 10.1038/289366a0
pubmed: 7464906
Xu, R. et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357–360 (2010).
pubmed: 20339031
pmcid: 2897825
doi: 10.1126/science.1186430
Krause, J. C. et al. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 85, 10905–10908 (2011).
pubmed: 21849447
pmcid: 3187471
doi: 10.1128/JVI.00700-11
Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012). http://www.nature.com/nature/journal/v489/n7417/abs/nature11414.html#supplementary-information ..
Hu, H. et al. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J. Virol. 86, 2978–2989 (2012).
pubmed: 22238297
pmcid: 3302345
doi: 10.1128/JVI.06665-11
Bouvier, N. M. & Lowen, A. C. Animal models for influenza virus pathogenesis and transmission. Viruses 2, 1530–1563 (2010).
pubmed: 21442033
pmcid: 3063653
doi: 10.3390/v20801530
Margine, I. & Krammer, F. Animal models for influenza viruses: implications for universal vaccine development. Pathogens 3, 845–874 (2014).
pubmed: 25436508
pmcid: 4282889
doi: 10.3390/pathogens3040845
Domnich, A. et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine 35, 513–520 (2017).
pubmed: 28024956
doi: 10.1016/j.vaccine.2016.12.011
Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190, 1837–1848 (2013).
pubmed: 23319732
doi: 10.4049/jimmunol.1201574
Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429.e410 (2018).
pubmed: 29625056
pmcid: 5890936
doi: 10.1016/j.cell.2018.03.030
Low, D. E. & McGeer, A. Pandemic (H1N1) 2009: assessing the response. CMAJ 182, 1874–1878 (2010).
pubmed: 20956501
pmcid: 2988536
doi: 10.1503/cmaj.100900
Harbury, P. B., Zhang, T., Kim, P. S. & Alber, T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262, 1401–1407 (1993).
pubmed: 8248779
doi: 10.1126/science.8248779
Spek, E. J., Bui, A. H., Lu, M. & Kallenbach, N. R. Surface salt bridges stabilize the GCN4 leucine zipper. Protein Sci. 7, 2431–2437 (1998).
pubmed: 9828010
pmcid: 2143877
doi: 10.1002/pro.5560071121
Magro, M. et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl Acad. Sci. 109, 3089–3094 (2012).
pubmed: 22323598
pmcid: 3286924
doi: 10.1073/pnas.1115941109
Knossow, M. et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302, 294–298 (2002).
pubmed: 12441073
doi: 10.1006/viro.2002.1625
Srivastava, V. et al. Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus. J. Virol. 87, 5831–5840 (2013).
pubmed: 23487456
pmcid: 3648183
doi: 10.1128/JVI.00273-13
DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143–151 (2014).
pubmed: 24412922
pmcid: 3966466
doi: 10.1038/nm.3443
de Vries, R. D. et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine https://doi.org/10.1016/j.vaccine.2016.11.082 (2016).
Webster, R. G. & Laver, W. G. Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. Virology 104, 139–148 (1980).
pubmed: 6156537
doi: 10.1016/0042-6822(80)90372-4
Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).
pubmed: 19079604
pmcid: 2596486
doi: 10.1371/journal.pone.0003942
Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246–251 (2009).
pubmed: 19251591
pmcid: 2758658
doi: 10.1126/science.1171491
Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343–1348 (2012).
pubmed: 22878502
pmcid: 3538841
doi: 10.1126/science.1222908
Sui, J. et al. Wide prevalence of heterosubtypic broadly neutralizing human anti–Influenza A antibodies. Clin. Infect. Dis. 52, 1003–1009 (2011).
pubmed: 21460314
doi: 10.1093/cid/cir121
Easterbrook, J. D. et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432, 39–44 (2012).
pubmed: 22727831
doi: 10.1016/j.virol.2012.06.003
Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, e02332–02317 (2018).
pubmed: 29615508
pmcid: 5885027
doi: 10.1128/mBio.02332-17
Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640–5649 (2012).
pubmed: 22535666
doi: 10.1182/blood-2012-01-380121
Isaacs, A. et al. Adjuvant selection for influenza and RSV prefusion subunit vaccines. Vaccines 9, 71 (2021).
pubmed: 33498370
pmcid: 7909420
doi: 10.3390/vaccines9020071
Short, K. R. et al. Using bioluminescent imaging to investigate synergism between Streptococcus pneumoniae and influenza A virus in infant mice. J. Vis. Exp. https://doi.org/10.3791/2357 (2011).
Szretter, K. J., Balish, A. L. & Katz, J. M. Influenza: propagation, quantification, and storage. Curr. Protoc. Microbiol. 3, 15G.11.11–15G.11.22 (2006).
doi: 10.1002/0471729256.mc15g01s3
Ishino, T. et al. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J. Biol. Chem. 288, 16529–16537 (2013).
pubmed: 23615911
pmcid: 3675588
doi: 10.1074/jbc.M113.457689
Frey, G. et al. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat. Struct. Mol. Biol. 17, 1486–1491 (2010).
pubmed: 21076402
pmcid: 2997185
doi: 10.1038/nsmb.1950
Gorny, M. K., VanCott, T. C., Williams, C., Revesz, K. & Zolla-Pazner, S. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Virology 267, 220–228 (2000).
doi: 10.1006/viro.1999.0095
pubmed: 10662617
Zuo, T. et al. Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. Nat. Commun. 6, 8855–8855 (2015).
doi: 10.1038/ncomms9855
pubmed: 26635249
Watterson, D. et al. A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance. Sci. Rep. 6, 22791–22791 (2016).
pubmed: 26976324
pmcid: 4792136
doi: 10.1038/srep22791
Amarilla, A. A. et al. An optimized high-throughput immuno-plaque assay for SARS-CoV-2. Front. Microbiol. 12, https://doi.org/10.3389/fmicb.2021.625136 (2021).
Yeolekar, L. R. et al. Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets. Vaccine 38, 6280–6290 (2020).
doi: 10.1016/j.vaccine.2020.07.043
pubmed: 32741671
Katzelnick, L. C. et al. Viridot: an automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Neglected Trop. Dis. 12, e0006862 (2018).
doi: 10.1371/journal.pntd.0006862